Are beta2-agonists responsible for increased mortality in heart failure?

European Journal of Heart Failure

Volumn 13, Issue 8, 2011, Pages 885-891

  Bermingham, Margaret ^a,b   Ocallaghan, Eleanor ^a   Dawkins, Ian ^a   Miwa, Saki ^c   Samsudin, Shazzarina ^a   McDonald, Kenneth ^a,b   Ledwidge, Mark ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Adrenergic agonists; Chronic obstructive pulmonary disease; Drugs; Heart failure; Mortality; Natriuretic peptides

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE;

AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MALE; RETROSPECTIVE STUDIES;

EID: 79961057530     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfr063     Document Type: Article

References (29)

1. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130-139.
2. Mulrow CD, Lucey CR, Farnett LE. Discriminating causes of dyspnea through clinical examination. J Gen Intern Med 1993;8:383-392. (Pubitemid 23214016)
3. Pearson SB, Pearson EM, Mitchell JR. The diagnosis and management of patients admitted to hospital with acute breathlessness. Postgrad Med J 1981;57:419-424. (Pubitemid 11064102)
4. Phillips SM, Marton RL, Tofler GH. Barriers to diagnosing and managing heart failure in primary care. Med J Aust 2004;181:78-81. (Pubitemid 39069568)
5. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002;121:846-851. (Pubitemid 34251453)
6. Lemaitre RN, Siscovick DS, Psaty BM, Pearce RM, Raghunathan TE, Whitsel EA, Weinmann SA, Anderson GD, Lin D. Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 2002;113:711-716. (Pubitemid 36044695)
7. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004;148:915-920.
8. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964-1969. (Pubitemid 36706719)
9. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, Maggioni AP, McMurray JJ. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010;12:557-565.
10. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569. (Pubitemid 30080872)
11. Coughlin SS, Metayer C, McCarthy EP, Mather FJ, Waldhorn RE, Gersh BJ, DuPraw S, Baughman KL. Respiratory illness, beta-agonists, and risk of idiopathic dilated cardiomyopathy. The Washington, DC, Dilated Cardiomyopathy Study. Am J Epidemiol 1995;142:395-403.
12. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002;110(6 Suppl.):S322-S328.
13. Awan NA, Needham K, Evenson MK, Hermanovich J, Joye JA, DeMaria AN, Mason DT. Therapeutic efficacy or oral pirbuterol in severe chronic congestive heart failure: acute hemodynamic and long-term ambulatory evaluation. Am Heart J 1981;102(Pt 2):555-563. (Pubitemid 11018140)
14. Ng TM, Munger MA, Lombardi WL, Doing TH, Ryujin DT, Young DC, Lugo RA. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol 2002;40:140-145. (Pubitemid 34705541)
15. Slutsky R. Hemodynamic effects of inhaled terbutaline in congestive heart failure patients without lung disease: beneficial cardiotonic and vasodilator beta-agonist properties evaluated by ventricular catheterization and radionuclide angiography. Am Heart J 1981;101:556-560. (Pubitemid 11120518)
16. Timmis AD, Bergman G, Walker L, Monaghan MJ, Jewitt DE. Potential value of oral beta 2-adrenoceptor agonists in congestive heart failure: a haemodynamic and metabolic study. Int J Cardiol 1984;5:327-338. (Pubitemid 14192682)
17. Wang RY, Tse TF, Yu DY, Lee PK, Sum MS, Chow MS. Beneficial hemodynamic effects of intravenous terbutaline in patients with severe heart failure. Am Heart J 1982;104(Pt 1):1016-1021. (Pubitemid 13157905)
18. Ledwidge M, Travers B, Ryder M, Ryan E, McDonald K. Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. Eur J Heart Fail 2004;6:235-243. (Pubitemid 38249368)
19. McDonald K, Ledwidge M, Cahill J, Quigley P, Maurer B, Travers B, Ryder M, Kieran E, Timmons L, Ryan E. Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. J Card Fail 2002;8:142-148. (Pubitemid 34857279)
20. Global Initiative for Chronic Obstructive Pulmonary Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2009. Available from: http://www.goldcopd.org.
21. Joint Formulary Committee. Chapter 3, respiratory system. In: British National Formulary. 54th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2009.
22. Rutten FH, Cramer MJ, Grobbee DE, Sachs AP, Kirkels JH, Lammers JW, Hoes AW. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005;26:1887-1894. (Pubitemid 41253302)
23. Inoue Y, Kawayama T, Iwanaga T, Aizawa H. High plasma brain natriuretic peptide levels in stable COPD without pulmonary hypertension or cor pulmonale. Intern Med 2009;48:503-512.
24. Gemici G, Erdim R, Celiker A, Tokay S, Ones T, Inanir S, Oktay A. B-type natriuretic peptide levels in patients with COPD and normal right ventricular function. Adv Ther 2008;25:674-680.
25. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002;137:715-725. (Pubitemid 35265315)
26. Goldsmith SR, Francis GS, Cohn JN. Norepinephrine infusions in congestive heart failure. Am J Cardiol 1985;56:802-804. (Pubitemid 16173077)
27. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-1263.
28. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010;55:1780-1787.
29. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-887.